Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
DMAC Stock Chart & Stats
$5.93
-$0.24(-4.23%)
At close: 4:00 PM EST
$5.93
-$0.24(-4.23%)
Day’s Range― - ―
52-Week Range$3.19 - $7.49
Previous CloseN/A
Volume70.76K
Average Volume (3M)300.55K
Market Cap
$308.82M
Enterprise Value$285.91M
Total Cash (Recent Filing)$55.32M
Total Debt (Recent Filing)$266.00K
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Mar 31, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding52,077,440
10 Day Avg. Volume376,738
30 Day Avg. Volume300,550
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.39
Price to Sales (P/S)0.00
P/FCF Ratio-9.93
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue20.71
Enterprise Value/Gross Profit41.43
Enterprise Value/Ebitda-8.62
Forecast
1Y Price Target
$17.00Price Target Upside186.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThere is high interest from key opinion leaders to participate in the next Phase II trial, highlighting the drug's clean safety and promising profile.
Drug DevelopmentDM199 has significant promise in treating preeclampsia, with early signs of improved placental perfusion.
Expert OpinionsKey opinion leaders are enthusiastic about DM199's potential to treat both hypertension and endothelial dysfunction, which could drastically improve maternal-fetal outcomes.
Bears Say
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $3.19 and its highest was $7.49 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $308.82M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Mar 31, 2026 which is in 133 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.01.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 52,077,440 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went down -14.105%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
Diamedica Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (186.68% Upside)
$17.00 (186.68% Upside)
Blogger Sentiment
Neutral
DMAC Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.93%
12-Months-Change
Fundamentals
Return on Equity
-64.12%
Trailing 12-Months
Asset Growth
8.61%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
Diamedica Therapeutics (DMAC) is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. The company leverages its expertise in therapeutic innovation to address unmet medical needs, primarily within the sectors of neurology and nephrology. Diamedica's core products include investigational therapies aimed at treating acute ischemic stroke and chronic kidney disease.
DMAC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook for DiaMedica Therapeutics. While there were positive developments in the preeclampsia program and a strong cash position, challenges such as slow enrollment in the stroke trial and increased operating expenses indicate areas of concern.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$17.00
▲(186.68% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
43.46% Insiders
4.35% Mutual Funds
― Other Institutional Investors
49.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---